Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg
and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains
no active drug), administered once-daily for 12 weeks, in diabetic subjects with symptoms
associated with gastroparesis.